232 related articles for article (PubMed ID: 36399432)
1. Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.
De Sarkar N; Patton RD; Doebley AL; Hanratty B; Adil M; Kreitzman AJ; Sarthy JF; Ko M; Brahma S; Meers MP; Janssens DH; Ang LS; Coleman IM; Bose A; Dumpit RF; Lucas JM; Nunez TA; Nguyen HM; McClure HM; Pritchard CC; Schweizer MT; Morrissey C; Choudhury AD; Baca SC; Berchuck JE; Freedman ML; Ahmad K; Haffner MC; Montgomery RB; Corey E; Henikoff S; Nelson PS; Ha G
Cancer Discov; 2023 Mar; 13(3):632-653. PubMed ID: 36399432
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
[TBL] [Abstract][Full Text] [Related]
4. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Herberts C; Annala M; Sipola J; Ng SWS; Chen XE; Nurminen A; Korhonen OV; Munzur AD; Beja K; Schönlau E; Bernales CQ; Ritch E; Bacon JVW; Lack NA; Nykter M; Aggarwal R; Small EJ; Gleave ME; ; Quigley DA; Feng FY; Chi KN; Wyatt AW
Nature; 2022 Aug; 608(7921):199-208. PubMed ID: 35859180
[TBL] [Abstract][Full Text] [Related]
5. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling.
Grolleau E; Candiracci J; Lescuyer G; Barthelemy D; Benzerdjeb N; Haon C; Geiguer F; Raffin M; Hardat N; Balandier J; Rabeuf R; Chalabreysse L; Wozny AS; Rommelaere G; Rodriguez-Lafrasse C; Subtil F; Couraud S; Herzog M; Payen-Gay L
Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627320
[TBL] [Abstract][Full Text] [Related]
6. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
7. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
8. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
9. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells.
Andreu-Vieyra C; Lai J; Berman BP; Frenkel B; Jia L; Jones PA; Coetzee GA
Mol Cell Biol; 2011 Dec; 31(23):4648-62. PubMed ID: 21969603
[TBL] [Abstract][Full Text] [Related]
10. Clinical Circulating Tumor DNA Testing for Precision Oncology.
Kim H; Park KU
Cancer Res Treat; 2023 Apr; 55(2):351-366. PubMed ID: 36915242
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
13. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
16. Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA.
Ritch E; Wyatt AW
Urol Oncol; 2018 Aug; 36(8):380-384. PubMed ID: 29248429
[TBL] [Abstract][Full Text] [Related]
17. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
19. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
[TBL] [Abstract][Full Text] [Related]
20. Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer.
Oliveira KCS; Ramos IB; Silva JMC; Barra WF; Riggins GJ; Palande V; Pinho CT; Frenkel-Morgenstern M; Santos SEB; Assumpcao PP; Burbano RR; Calcagno DQ
Mol Cancer Res; 2020 Apr; 18(4):517-528. PubMed ID: 31996469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
